Conditions & Recovery · STAT News · October 15, 2026

Compass Pathways CEO: Psychedelics company will ‘go slow before we go fast’

The CEO of Compass Pathways said the company, whose psychedelic therapy is set for regulatory review this year, is prepared to “go slow before we go fast.”

Originally published by STAT News. We curate and add context; they did the reporting.

Read the full story at STAT News ↗

Related learning

Biotech Firm Claims Some Credit for Groundbreaking Virus Research Biotech Firm Claims Some Credit for Groundbreaking Virus Research James P. Allison, Ph.D., bangs gong after completing proton therapy treatment Combination therapy helps plasmacytoid bladder cancer survivor